NeoGenomics Operating Cycle from 2010 to 2026

NEO Stock  USD 12.10  0.04  0.33%   
NeoGenomics Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 88.06. During the period from 2010 to 2026, NeoGenomics Operating Cycle quarterly data regression pattern had sample variance of  1,134 and median of  109.83. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
98.58
Current Value
88.06
Quarterly Volatility
33.66784952
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check NeoGenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoGenomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.6 M, Interest Expense of 8 M or Selling General Administrative of 272.7 M, as well as many indicators such as Price To Sales Ratio of 0.69, Dividend Yield of 0.0059 or PTB Ratio of 0.51. NeoGenomics financial statements analysis is a perfect complement when working with NeoGenomics Valuation or Volatility modules.
  
Build AI portfolio with NeoGenomics Stock
Check out the analysis of NeoGenomics Correlation against competitors.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
Evaluating NeoGenomics's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into NeoGenomics's fundamental strength.

Latest NeoGenomics' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of NeoGenomics over the last few years. It is NeoGenomics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeoGenomics' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

NeoGenomics Operating Cycle Regression Statistics

Arithmetic Mean119.53
Geometric Mean116.03
Coefficient Of Variation28.17
Mean Deviation21.98
Median109.83
Standard Deviation33.67
Sample Variance1,134
Range128
R-Value(0.38)
Mean Square Error1,033
R-Squared0.15
Significance0.13
Slope(2.55)
Total Sum of Squares18,136

NeoGenomics Operating Cycle History

2026 88.06
2025 98.58
2024 109.54
2023 106.39
2022 113.25
2021 113.23
2020 129.43

About NeoGenomics Financial Statements

NeoGenomics investors utilize fundamental indicators, such as Operating Cycle, to predict how NeoGenomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 98.58  88.06 

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving against NeoGenomics Stock

  0.73DVA DaVita HealthCarePairCorr
  0.69BZ7A Bumrungrad HospitalPairCorr
  0.59SIG Sigma HealthcarePairCorr
  0.587QD CLOVER HEALTH INVPairCorr
  0.574WK Wenzhou Kangning HospitalPairCorr
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out the analysis of NeoGenomics Correlation against competitors.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.306
Earnings Share
(0.87)
Revenue Per Share
5.552
Quarterly Revenue Growth
0.119
Return On Assets
(0.03)
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.